DGAP-News: MeVis Medical Solutions AG / Key word(s): Statement/Offer MeVis Medical Solutions AG: Joint Reasoned Statement of Executive Board and Supervisory Board of MeVis Medical Solutions AG 06.02.2015 / 09:30 --------------------------------------------------------------------- Voluntary public takeover offer of VMS Deutschland Holdings GmbH - Executive and Supervisory Board publish joint statement - Varian Medical Systems is seen as reliable partner for MeVis' development - Recommendation to the shareholders to accept the offer Bremen, Februar 6, 2015 - Executive Board and Supervisory Board of MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, today published a joint statement pursuant to § 27 of the German Securities Acquisition and Takeover Act (WpÜG) on the voluntary public takeover offer (cash offer) of VMS Germany Holdings GmbH, Darmstadt, issued to the shareholders of MeVis Medical Solutions AG on January 27, 2015. VMS Deutschland Holdings GmbH based in Darmstadt, an affiliate of Varian Medical Systems, Inc., Palo Alto, California, USA, published a voluntary public takeover offer on January 27th, 2015 to all shareholders of MeVis Medical Solutions AG to acquire their registered non-par value shares against payment of 17.50 Euros per share. The offer is subject to the condition of a minimum acceptance rate of 75 % of the shares issued by MeVis Medical Solutions AG (excluding treasury shares). Varian Medical Systems has become the world's leading manufacturer of medical devices and software for treating cancer and other diseases through radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies software systems for radiation clinics, radiotherapy centers and medical oncology practices. Varian is also a premier supplier of X-ray imaging components, including tubes, digital detectors and image processing software and workstations for use in medical, scientific and industrial settings, and produces X-ray systems for cargo screening and industrial inspection applications. Varian Medical Systems employs approximately 6,800 employees at operating plants in North America, Europe and China and approximately 75 sales and customer service centers worldwide. The publication of the Offer Document by VMS Germany Holdings GmbH and further information, relevant to the tender offer, is made available in the internet at http://www.variango1.de. The Executive Board and Supervisory Board welcome the offer and consider Varian Medical Systems a reliable partner for the further development of the MeVis Medical Solutions AG. They regard the offered cash consideration of 17.50 Euros per share appropriate and are of the opinion that the transaction is in the interest of MeVis Medical Solutions AG and their shareholders. The Executive Board and Supervisory Board recommend all MeVis shareholders to accept the offer. "Various new sales channels for our existing products will arise with Varian as a new shareholder, as Varian, in its Imaging Components business, has already built intensive customer relationships with almost all important global medical device manufacturers", said Marcus Kirchhoff, CEO of MeVis Medical Solutions AG. He continued: "The affiliation with Varian also allows us, in the medium term, the development of other software products for new market segments." "Our previously strong dependency on the highly profitable Digital Mammography Segment has long been a risk for MeVis. Due to the planned change in the collaboration in medium- and long-term, which was announced in January 2014, and its associated reduction of business activities with Hologic, this risk had become more concrete." added Dr. Robert Hannemann, CFO of MeVis Medical Solutions AG. "With Varian as a new major shareholder it is expected that this dependency is significantly reduced." The full text of the joint statement is published in the Internet at www.mevis.de under Investor Relations/ Aktie/ Übernahmeangebot in German language and is held available free of charge at MeVis Medical Solutions AG, Investor Relations, Caroline Herschel-Strasse 1, 28359 Bremen, Tel: +49 (0) 421-22495 0 Fax: +49 (0) 421-22495 499, E-mail: [email protected]. --------------------------------------------------------------------- 06.02.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: MeVis Medical Solutions AG Caroline-Herschel-Str. 1 28359 Bremen Germany Phone: +49 421 224 95 0 Fax: +49 421 224 95 999 E-mail: [email protected] Internet: http://www.mevis.de ISIN: DE000A0LBFE4 WKN: A0LBFE Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 320385 06.02.2015